+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting ESAs Market by Product Type (Biosimilar, Originator), Indication (Chemotherapy Induced Anemia, Chronic Kidney Disease Induced Anemia, Premature Birth Induced Anemia), Route of Administration, End User - Global Forecast 2025-2030- Product Image
Long-acting ESAs Market by Product Type (Biosimilar, Originator), Indication (Chemotherapy Induced Anemia, Chronic Kidney Disease Induced Anemia, Premature Birth Induced Anemia), Route of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Long-acting ESAs Market by Product Type (Biosimilar, Originator), Indication (Chemotherapy Induced Anemia, Chronic Kidney Disease Induced Anemia, Premature Birth Induced Anemia), Route of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118180
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Long-acting erythropoiesis-stimulating agents have redefined the approach to anemia management by extending dosing intervals and improving patient quality of life. These biotherapeutics build upon foundational treatments introduced decades ago, offering enhanced molecular stability and sustained receptor engagement. As a result, clinicians can reduce the frequency of injections and focus on holistic patient care rather than repetitive administration schedules.

In recent years, advances in protein engineering and formulation science have driven the development of longer-acting derivatives such as darbepoetin alfa and novel analogues. The extended half-life of these agents enables more predictable hemoglobin responses, supports adherence to treatment protocols, and aligns with value-based healthcare objectives. Meanwhile, patients experience fewer disruptions to daily life and reduced clinic visits, which has become a critical factor in therapy selection.

Against this backdrop, the long-acting ESA sector has attracted growing attention from drug developers, payers, and healthcare providers aiming to balance clinical efficacy with cost considerations. By examining regulatory approvals, emerging biosimilars, and patient-centered innovations, stakeholders can gain actionable insights. This executive summary delivers a structured overview of recent trends, challenges, and strategic imperatives in the evolving long-acting ESA landscape.

Identifying Fundamental Shifts Reshaping the Long-Acting ESA Landscape Driven by Innovation, Patient Preferences, and Evolving Clinical Protocols

The landscape of long-acting erythropoiesis-stimulating agents is undergoing transformative shifts propelled by technological breakthroughs and evolving stakeholder priorities. Biopharmaceutical innovators are adopting advanced glycosylation and fusion protein techniques that extend half-life without compromising safety profiles. Consequently, pipeline candidates are increasingly designed to reduce immunogenicity risks and address a broader range of anemia indications.

Concurrently, payers and healthcare systems are placing greater emphasis on value-based contracting models that reward sustained clinical outcomes and cost efficiencies. This trend has led to novel reimbursement structures that incentivize both brand and biosimilar sponsors to demonstrate real-world effectiveness. As a result, the distinction between originator products and biosimilars has blurred, encouraging head-to-head clinical assessments and comparative real-world studies.

Moreover, the patient voice has gained prominence in shaping treatment paradigms. Telehealth integration, digital adherence tools, and patient support programs now accompany ESA therapy plans, fostering more personalized regimens. In parallel, regulatory agencies have accelerated approval pathways for follow-on biologics while enforcing stringent pharmacovigilance guidelines. Together, these factors are redefining competitive dynamics and enabling stakeholders to navigate an increasingly complex ecosystem.

Assessing the Cumulative Impact of United States Tariff Policy Changes for 2025 on the Global Distribution and Accessibility of Long-Acting ESAs

As of 2025, United States tariff policy changes have introduced new considerations for manufacturers, distributors, and healthcare providers in the global long-acting ESA supply chain. Higher import duties on certain biotherapeutic APIs and finished drug products have elevated production costs for companies with manufacturing bases outside North America. This situation has prompted many organizations to reassess manufacturing footprints and leverage domestic contract development and manufacturing organizations to mitigate exposure to trade-related expenses.

In response, pharmaceutical firms have employed strategic initiatives such as nearshoring critical production steps, negotiating long-term supply agreements, and exploring tariff exclusion requests through U.S. customs channels. These measures aim to balance cost containment with the imperative to maintain continuous patient access. At the same time, trade policy shifts have spurred conversations around regulatory harmonization, as stakeholders seek to streamline cross-border data sharing and quality inspections to avoid redundant costs.

Moving forward, the interplay between tariff adjustments and market access strategies will demand close collaboration among policy makers, industry associations, and healthcare payers. Organizations that proactively integrate supply chain resilience into their strategic planning will be best positioned to sustain product availability, manage pricing pressures, and uphold patient care standards in the evolving long-acting ESA market.

Unlocking Key Segmentation Insights to Illuminate Market Dynamics by Product Type, Indication, Administration Route, and End User Variations

Within the product type segmentation the market is studied across biosimilar and originator categories. The biosimilar segment is further studied across darbepoetin alfa and epoetin beta, reflecting the growing influence of follow-on biologics that offer cost-effective alternatives. Similarly, the originator segment is further studied across darbepoetin alfa and epoetin beta, showcasing the established molecules that continue to set the efficacy benchmark for novel entrants.

In the indication segmentation the market is studied across chemotherapy induced anemia, chronic kidney disease induced anemia, and premature birth induced anemia. Each clinical scenario presents unique therapeutic demands and patient profiles, from supporting transfusion-dependent individuals undergoing cancer treatment to addressing persistent erythropoietic deficits in neonatal populations.

Within the route of administration segmentation the market is studied across intravenous and subcutaneous delivery systems. Intravenous formulations often facilitate administration in hospital settings, while subcutaneous injections empower patients and caregivers to manage therapy at home, reducing the burden on outpatient facilities.

For the end user segmentation the market is studied across clinics, home care, and hospitals. The clinics segment is further studied across ambulatory care clinics and specialty clinics, recognizing the variation in care settings. The home care segment is further studied across nurse assisted administration and self administration, reflecting different levels of patient or caregiver involvement. The hospitals segment is further studied across private hospitals and public hospitals, emphasizing the divergent operational models and purchasing channels in institutional care.

Revealing Crucial Regional Insights Highlighting the Role of the Americas, Europe-Middle East-Africa, and Asia-Pacific Markets in ESA Adoption Trends

In the Americas region, the interplay between advanced healthcare infrastructure and dynamic reimbursement frameworks accelerates adoption of long-acting ESAs. North American markets benefit from concentrated product launches and established distribution channels, whereas Latin American jurisdictions navigate varying regulatory timelines and evolving formulary inclusion criteria.

Within Europe, Middle East & Africa, regulatory harmonization under initiatives such as the European Medicines Agency’s centralized approval process has streamlined cross-border access to novel ESA therapies. Growth in emerging MENA markets is driven by increased healthcare spending, while established Western European markets emphasize real-world evidence to support biosimilar uptake.

In Asia-Pacific, rapidly expanding patient populations and government initiatives to improve anemia care access underscore the significance of both originator agents and biosimilars. Regulatory authorities in countries such as Japan and Australia have adopted rigorous comparability guidelines, while markets in Southeast Asia and South Asia are prioritizing cost containment to extend treatment access.

Detailing Strategic Intelligence on Leading Industry Participants Driving Innovation, Partnerships, and Competitive Positioning Within the Long-Acting ESA Sector

Leading industry participants are channeling resources into pipeline innovation to secure a competitive edge. Amgen continues to optimize its long-acting portfolio through molecular refinements that aim to extend half-life and minimize injection frequency. Sandoz and Teva are advancing biosimilar candidates designed to match reference product profiles while leveraging cost advantages to gain payer support.

Strategic alliances have emerged as a core component of growth strategies. Collaborations between established biologics developers and contract manufacturing organizations are enabling scalable production of complex glycoproteins. Partnerships with digital health companies are delivering patient engagement platforms that bolster adherence and capture real-world outcome data, thereby strengthening value propositions.

At the same time, mid-sized biopharma firms are exploring niche indications and regional launches to differentiate their offerings. Clinical trial networks focusing on underrepresented patient groups have expanded insights into rare anemia subtypes and neonatal populations. This diversification reduces reliance on saturated segments and opens new avenues for product positioning.

Presenting Actionable Recommendations for Industry Leaders to Navigate Regulatory Landscapes, Enhance Patient Outcomes, and Optimize Commercial Strategies in ESA Delivery

Industry leaders should engage proactively with regulatory agencies to shape guidelines for long-acting ESA approvals and post-marketing surveillance. By participating in advisory committees and contributing to draft guidance documents, companies can influence data requirements and facilitate smoother market entries.

Furthermore, investing in patient support programs that incorporate educational resources, medication reminders, and virtual care coordination will enhance adherence and improve clinical outcomes. Integrating digital adherence tools can also generate valuable real-world evidence, which in turn strengthens reimbursement dialogues with payers.

To navigate evolving tariff environments and supply chain complexities, organizations should diversify manufacturing and sourcing locations. Establishing regional manufacturing hubs and securing multiple supplier agreements will mitigate disruption risks and preserve consistent product availability across key markets.

Finally, forging cross-sector partnerships-such as alliances with health technology providers, academic research centers, and specialty pharmacies-will foster comprehensive care models. These collaborations will align clinical, operational, and commercial objectives, ultimately driving sustainable growth in the long-acting ESA landscape.

Explaining the Rigorous Multimodal Research Methodology Underpinning Comprehensive Analysis of Long-Acting ESA Market Dynamics and Competitive Forces

Our research methodology commenced with an extensive review of primary sources, including peer-reviewed journals, regulatory filings, and clinical trial registries. These documents established the scientific underpinnings of long-acting erythropoiesis-stimulating agent development and highlighted recent approvals, label expansions, and safety communications.

Subsequently, we conducted in-depth interviews with key opinion leaders spanning clinical hematologists, oncology specialists, pharmacovigilance experts, and healthcare payers. These qualitative insights enriched our understanding of real-world treatment patterns, adherence barriers, and emerging indications, ensuring our analysis reflects practical considerations.

We then synthesized secondary data from industry publications, health authority databases, and corporate disclosures to map competitive positioning and strategic initiatives. Data triangulation techniques reconciled discrepancies across sources and enhanced the robustness of our findings. This process was underpinned by rigorous validation checks and scenario analyses to test sensitivity to policy shifts and pricing dynamics.

Finally, cross-functional collaboration among our research, analytics, and editorial teams facilitated iterative reviews, guaranteeing that the final deliverable presents a cohesive narrative and actionable intelligence for decision makers in the long-acting ESA domain.

Concluding the Executive Summary with Strategic Reflection on Long-Acting ESA Developments, Challenges Overcome, and Opportunities on the Horizon for Stakeholders

In summary, the long-acting erythropoiesis-stimulating agent landscape is characterized by sustained innovation, evolving regulatory frameworks, and growing emphasis on patient-centric care. The convergence of advanced molecular engineering, biosimilar pathways, and digital health integration has reshaped competitive dynamics and opened new avenues for differentiation.

Stakeholders who navigate tariff policy shifts effectively and embrace strategic partnerships will unlock value across global markets. By aligning clinical trial designs with payer evidence requirements and reinforcing supply chain resilience, organizations can secure leadership positions and ensure uninterrupted therapy access for patients.

Ultimately, the future of long-acting ESAs will hinge on collaborative efforts between biopharmaceutical manufacturers, healthcare providers, policy makers, and patient communities. Together, they can drive continual improvement in anemia management, enhance affordability, and expand care access. This executive summary provides a foundation for informed decision making and strategic planning as the industry enters its next phase of growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Product Type
    • Biosimilar
      • Darbepoetin Alfa
      • Epoetin Beta
    • Originator
      • Darbepoetin Alfa
      • Epoetin Beta
  • Indication
    • Chemotherapy Induced Anemia
    • Chronic Kidney Disease Induced Anemia
    • Premature Birth Induced Anemia
  • Route Of Administration
    • Intravenous
    • Subcutaneous
  • End User
    • Clinics
      • Ambulatory Care Clinics
      • Specialty Clinics
    • Home Care
      • Nurse Assisted Administration
      • Self Administration
    • Hospitals
      • Private Hospitals
      • Public Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Comparative cost-effectiveness analyses of long-acting ESAs versus biosimilars in European dialysis populations
5.2. Integration of digital patient monitoring tools to improve adherence to extended dosing schedules of ESAs
5.3. Impact of novel pegylation technologies on dosing intervals and patient quality of life in chronic kidney disease anemia patients
5.4. Strategic partnerships between biopharma and specialty pharmacies to optimize home administration of long-acting ESAs
5.5. Adoption of value-based contracting models for long-acting ESAs tied to real-world anemia management outcomes
5.6. Regulatory pathways and expedited approval trends for next-generation long-acting erythropoietin receptor agonists in global markets
5.7. Emerging market expansions driving demand for stable refrigeration-independent long-acting ESAs in rural healthcare settings
5.8. Pipeline innovation focusing on non-heme iron-independent long-acting ESAs to reduce cardiovascular risk factors in CKD patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting ESAs Market, by Product Type
8.1. Introduction
8.2. Biosimilar
8.2.1. Darbepoetin Alfa
8.2.2. Epoetin Beta
8.3. Originator
8.3.1. Darbepoetin Alfa
8.3.2. Epoetin Beta
9. Long-acting ESAs Market, by Indication
9.1. Introduction
9.2. Chemotherapy Induced Anemia
9.3. Chronic Kidney Disease Induced Anemia
9.4. Premature Birth Induced Anemia
10. Long-acting ESAs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
11. Long-acting ESAs Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Ambulatory Care Clinics
11.2.2. Specialty Clinics
11.3. Home Care
11.3.1. Nurse Assisted Administration
11.3.2. Self Administration
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Americas Long-acting ESAs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Long-acting ESAs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Long-acting ESAs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Amgen Inc.
15.3.2. F. Hoffmann-La Roche Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LONG-ACTING ESAS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING ESAS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. LONG-ACTING ESAS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. LONG-ACTING ESAS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. LONG-ACTING ESAS MARKET: RESEARCHAI
FIGURE 24. LONG-ACTING ESAS MARKET: RESEARCHSTATISTICS
FIGURE 25. LONG-ACTING ESAS MARKET: RESEARCHCONTACTS
FIGURE 26. LONG-ACTING ESAS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING ESAS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING ESAS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING ESAS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY EPOETIN BETA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CHEMOTHERAPY INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CHEMOTHERAPY INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CHRONIC KIDNEY DISEASE INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PREMATURE BIRTH INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PREMATURE BIRTH INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY AMBULATORY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY AMBULATORY CARE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES LONG-ACTING ESAS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 110. CANADA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 111. CANADA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 112. CANADA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 113. CANADA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. CANADA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. CANADA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. CANADA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 120. CANADA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 121. CANADA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 122. CANADA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 123. CANADA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 124. CANADA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 128. MEXICO LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 129. MEXICO LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 130. MEXICO LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 131. MEXICO LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. MEXICO LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING ESAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 218. GERMANY LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 219. GERMANY LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 220. GERMANY LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 221. GERMANY LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 222. GERMANY LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 223. GERMANY LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. GERMANY LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 232. GERMANY LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 233. GERMANY LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 238. FRANCE LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 239. FRANCE LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 240. FRANCE LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 241. FRANCE LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FRANCE LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 250. FRANCE LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 251. FRANCE LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. ITALY LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. ITALY LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. ITALY LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 274. ITALY LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 275. ITALY LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 276. ITALY LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 277. ITALY LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. ITALY LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. ITALY LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. ITALY LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. ITALY LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ITALY LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. ITALY LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 284. ITALY LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 285. ITALY LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 286. ITALY LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 287. ITALY LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. ITALY LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. SPAIN LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. SPAIN LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. SPAIN LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 292. SPAIN LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 293. SPAIN LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 294. SPAIN LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 295. SPAIN LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. SPAIN LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. SPAIN LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. SPAIN LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. SPAIN LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. SPAIN LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SPAIN LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 304. SPAIN LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 305. SPAIN LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 326. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 328. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA LONG-ACTING ESAS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 343. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 344. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 346. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2018-2024 (USD MILLION)
TABLE 348. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY ORIGINATOR, 2025-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 350. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 352. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 354. SOUTH AFRICA LONG-ACTING ESAS MARKET SIZE, BY E

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Long-acting ESAs market report include:
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Related Reports

Cancer Supportive Care - Global Strategic Business Report - Product Image

Cancer Supportive Care - Global Strategic Business Report

  • Report
  • 262 Pages
  • Global
From
Mircera Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Mircera Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Renal Anemia Treatment - Global Strategic Business Report - Product Image

Renal Anemia Treatment - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Renal Anemia Market Report and Forecast 2025-2034 - Product Image

Renal Anemia Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.